Thụy Sĩ - Tiếng Đức - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - osimertinibum - filmtabletten - osimertinibum 40 mg ut osimertinibi mesilas 47.7 mg, mannitolum 147 mg, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, natrii stearylis fumaras corresp. natrium 0.3 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - nicht-kleinzelliges lungenkarzinom - synthetika

Thụy Sĩ - Tiếng Đức - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - osimertinibum - filmtabletten - osimertinibum 80 mg ut osimertinibi mesilas 95.4 mg, mannitolum 295 mg, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, natrii stearylis fumaras corresp. natrium 0.6 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - nicht-kleinzelliges lungenkarzinom - synthetika

Liên Minh Châu Âu - Tiếng Đức - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - karzinom, nicht kleinzellige lunge - andere antineoplastische wirkstoffe, die protein-kinase-inhibitoren - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Đức - Tiếng Đức - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

onkovis gmbh (8111905) - carboplatin - infusionslösung - teil 1 - infusionslösung; carboplatin (23168) 50 milligramm

Liên Minh Châu Âu - Tiếng Đức - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastische mittel - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Thụy Sĩ - Tiếng Đức - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - mobocertinibum - hartkapseln - mobocertinibum 40 mg ut mobocertinibi succinas 48.06 mg, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - nicht-resezierbares oder metastasiertes nicht-kleinzelliges lungenkarzinom (nsclc) mit exon- 20-insertionsmutation des epidermalen wachstumsfaktor-rezeptors (egfr) - synthetika

Thụy Sĩ - Tiếng Đức - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - cobimetinibum - filmtabletten - cobimetinibum 20 mg ut cobimetinibi hemifumaras, cellulosum microcristallinum, lactosum monohydricum 36.48 mg, carmellosum natricum conexum corresp. natrium max. 0.99 mg, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, pro compresso obducto. - onkologikum - synthetika

Liên Minh Châu Âu - Tiếng Đức - EMA (European Medicines Agency)

roche registration gmbh - cobimetinib hemifumarat - melanom - antineoplastische mittel - cotellic ist indiziert zur anwendung in kombination mit vemurafenib zur behandlung von erwachsenen patienten mit inoperablem oder metastasiertem melanom mit einer braf-v600-mutation.

Đức - Tiếng Đức - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

abz-pharma gmbh - geschäftsanschrift - (4238075) - itraconazol - hartkapsel - teil 1 - hartkapsel; itraconazol (23401) 100 milligramm

Đức - Tiếng Đức - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ratiopharm gmbh (3087881) - itraconazol - hartkapsel - teil 1 - hartkapsel; itraconazol (23401) 100 milligramm